18671-97-1

Basic information

• Product Name: 2,6-Dichloroquinoxaline
• Synonyms: 2,6-DICHLOROQUINOXALINE;SALOR-INT L300268-1EA;2,6-DICHLOROQUINOXALINE 95%;Quinoxaline, 2,6-dichloro- (6CI,7CI,8CI,9CI);Quinoxaline, 2,6-dichloro-
• CAS NO: 18671-97-1
• Molecular Formula: C₈H₄Cl₂N₂
• Molecular Weight: 199.04
• Product Categories: Quinoline&Isoquinoline;Miscellaneous;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Quinoxalines;QuinoxalinesHeterocyclic Building Blocks
• Mol File: 18671-97-1.mol
• Article Data: 11

Chemical Properties

• Melting Point: 153-157 °C(lit.)
• Boiling Point: 278.675 °C at 760 mmHg
• Flash Point: 149.078 °C
• Appearance: Crystalline powder
• Density: 1.486 g/cm³
• Vapor Pressure: 0.00711mmHg at 25°C
• Refractive Index: 1.67
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly, Heated)
• PKA: -2.42±0.30(Predicted)
• CAS DataBase Reference: 2,6-Dichloroquinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dichloroquinoxaline(18671-97-1)
• EPA Substance Registry System: 2,6-Dichloroquinoxaline(18671-97-1)

Safety Data

• Hazard Codes: T,Xn
• Statements: 25-38-41-37/38-22
• Safety Statements: 36/37/39-45-39-26
• WGK Germany: 3
• Hazardous Substances Data: 18671-97-1(Hazardous Substances Data)

Usage

Chemical Properties

Crystalline Powder

Uses

Different sources of media describe the Uses of 18671-97-1 differently. You can refer to the following data:
1. Intermediate for the production of herbicides Attributes For further information please contact us Contact
2. 2,6-Dichloroquinoxaline is an analogue of 3-amino-7-chloro-1,2,4-benzotriazine 1-oxide, an antimalarial agent.

InChI:InChI=1/C8H4Cl2N2/c9-5-1-2-6-7(3-5)11-4-8(10)12-6/h1-4H

Upstream product

• 2427-71-6 6-chloro-1,2-dihydroquinoxalin-2-one 
• 89-63-4 4-Chloro-2-nitroaniline 
• 95-83-0 4-Chloro-1,2-phenylenediamine 
• 2427-71-6 2-hydroxy-6-chloroquinoxaline 
• 68-12-2 N,N-dimethyl-formamide 
• 610-40-2 3,4-dinitro-chlorobenzene 
• 859307-61-2 ethyl 2-(4-chloro-2-nitrophenylamino)acetate 
• 89938-22-7 6-chloro-1,2,3,4-tetrahydroquinoxalin-2-one 
• 1196-57-2 quinoxalin-2⁽¹⁾-one 

Downstream Products

• 76578-79-5 6-chloro-2-(4-hydroxyphenoxy)quinoxaline 
• 1448-87-9 2-chloroquinoxaline 
• 78470-92-5 4-[N-methyl-N-(6-chloro-2-quinoxalinyl)amino]phenol 
• 174672-73-2 sodium salt of 4-(6-chloro-2-quinoxalyloxy)phenol 
• 1257089-73-8 N-benzyl-N-(6-chloroquinoxalin-2-yl)amine 

Relevant articles and documents

Synthesis of novel antibacterial and antifungal quinoxaline derivatives

A series of quinoxaline derivatives were designed, synthesized and evaluated as antimicrobial agents against plant pathogenic bacteria and fungi. Some of these compounds exhibited significant antibacterial and antifungal activities in vitro. Compound 5k d

Synthesis, antiviral and antibacterial activities and action mechanism of penta-1,4-dien-3-one oxime ether derivatives containing a quinoxaline moiety

A series of penta-1,4-dien-3-one oxime ether derivatives containing a quinoxaline moiety were synthesized and their antibacterial and antiviral activities were evaluated. Bioassay activity indicated that some of the compounds displayed significant antibacterial and antiviral activities. In particular, some title compounds were found to show remarkable antiviral activities against tobacco mosaic virus (TMV). Compound 6i showed remarkable curative, protective and inactivation activity against TMV, with a 50% effective concentration (EC50) of 287.1, 157.6 and 133.0 μg mL-1, respectively. These results were better than or comparable to those of ningnanmycin (356.3, 233.7 and 121.6 μg mL-1, respectively). Microscale thermophoresis (MST) also showed that the binding of compound 6i to TMV coat protein (TMV-CP) gave a Kd value of 0.115 ± 0.092 μmol L-1, which was better than that of ningnanmycin (0.523 ± 0.254 μmol L-1). Meanwhile, the EC50 values of compound 6k against Xanthomonas axonopodis pv. Citri (Xac) and Xanthomonas oryzae pv. oryzae (Xoo) were 16.8 and 33.4 μg mL-1 respectively, and that of compound 6i against Ralstonia solanacearum (Rs) was 33.9 μg mL-1. These results were better than those of bismerthiazol (44.3, 42.5 and 62.4 μg mL-1, respectively). The mechanism of antibacterial action of compound 6k against Xac was analysed through scanning electron microscopy (SEM). This study indicated that the title compounds are valuable in the search for novel agrochemicals.

Antitumor compositions and methods of treatment

This invention provides certain sulfonamidoquinoxaline derivatives and methods for using them in the treatment of susceptible neoplasms in mammals. Also provided are certain novel pharmaceutical formulations employing these sulfonamidoquinoxaline derivatives, in combination with a carrier, diluent or excipient.